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doi:10.1016/j.jtcvs.2006.01.025n 1912, a famous thoracic surgeon, Theodore Tuffier, was presented a young
patient with disabling symptoms caused by aortic stenosis. He planned to treat
the patient by using inflow occlusion cutting the aortic valve leaflets with a
nife. About to snare the cava, he noted that the aortic wall was flaccid, so he used
is finger to invaginate the anterior aortic wall through the valve orifice. Immedi-
tely the palpable systolic vibration of the aortic wall was diminished. When
xamined 12 years later, the patient was alive and well.1 Tuffier had performed the
rst successful closed heart surgery.
Aortic stenosis of the senile calcific variety is today the most common valvular
isease in the Western World, occurring in 2.9% of adults aged more than 65
ears.2-4 Its hemodynamic precursors include congenital bicuspid malformation and
cquired insults such as rheumatic heart disease, endocarditis, myxomatous prolif-
ration, and trauma, which progress to a combination of stenosis and regurgitation.2
nce symptoms, in particular left ventricular dysfunction, become manifest, the
rognosis is poor and medical therapy is not likely to modify the course of the
isease.4 Balloon valvuloplasty has been attempted but with only transient modest
mprovement and is reserved for palliation only.5 Open surgery therefore remains
he treatment of choice for symptomatic aortic stenosis, and open aortic valve
eplacement is exceedingly effective in eliminating symptoms and improving prog-
osis.6 Open surgery, however, necessarily entails the risks and morbidity associ-
ted with cardiopulmonary bypass, clamping of the aorta, myocardial preservation,
nd median sternotomy, with operative mortalities as high as 20% reported in
lderly patients and those with concomitant left ventricular dysfunction.7,8 Because
enile aortic stenosis is a disease of the elderly, comorbidities are a frequent concern
nd render some patients inoperable.
Ironically, nearly 100 years after Tuffier’s pioneering work, closed procedures
re again being reconsidered by cardiac surgeons as an option for aortic stenosis.9
atheter-based aortic valve implantation in animal models was introduced in
992,10,11 and 10 years later Cribier and colleagues12 described the first successful
uman aortic valve implantation using the venous antegrade transeptal approach.
ore recently at our institution, Webb and colleagues13 reported on patients treated
y retrograde arterial implantation of prosthetic aortic valves. Ye and colleagues9
eported on the deployment of an aortic valve prosthesis for severe aortic stenosis
hrough the apex of the left ventricle in a 75-year-old patient (a closed heart surgery
rocedure).
This report of successful implantation of an aortic valve prosthesis through the
pex of the left ventricle without sternotomy or the use of cardiopulmonary bypass
n a human9 provides a glimpse of an indispensable future role for cardiac surgery
ith this modality. At present this procedure is offered to patients deemed to be
onsurgical candidates, but we can fully expect the indications in the future to be
xpanded to high-risk surgical candidates and likely even further, depending on the
roven clinical durability of the device. Although clinical experience is obviously
imited, in vitro valve durability has been repeatedly documented to 200 million
ycles or more than 5 years of life.
Before the development of cardiopulmonary bypass by Gibbon in the 1950s,14
ardiac surgeons were ingenious in developing instruments for closed heart surgery.
xamples include the valvulotome and dilating forceps for pulmonary valvulotomy
nd the infundibular punch for right ventricular outflow tract obstruction.1,15 Indeed,
ow a lost art, the past era of cardiac surgeons were very comfortable with the
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Lranschamber approach to mitral stenosis, using a dilator
nd finger palpation as their guide.16 Modern developments
ave replaced the finely tuned perceptions of the surgeons’
ducated tactile sense with secondary visualization by flu-
roscopy and echocardiography. This should, however, not
issuade cardiac surgeons from embracing this evolving
odality simply because their instruments are now guided
y fluoroscopy and echocardiography rather than by palpa-
ion or direct vision.
The transapical ventricular approach is first and foremost
 surgical procedure15,16 and may well prove to be the route
f choice for closed heart aortic valve implantation. The
emoral venous access route used by Cribier and col-
eagues12 is a long tortuous road that may allow passage of
arge-profile valved stents and antegrade crossing of the
ortic valve but entails crossing the atrial septum and native
itral valve. This approach requires dilation of the atrial
eptum, increasing the risk of a significant atrial septal
efect and pericardial tamponade. High-risk, unstable pa-
ients may not tolerate the prolonged reduction in cardiac
utput resulting from the passage of a large-diameter cath-
ter through (and possible damage to) the native mitral
alve. By using this approach, Hanzel and colleagues17
eported an incidence of mitral valve injury that led to cardio-
ascular collapse and death. The arterial access approach, first
escribed in humans by Webb and colleagues,13 obviates
he need for transseptal puncture and avoids the potential
amage to the mitral valve but requires retrograde crossing
f the native stenotic aortic valve and is limited to a low-
rofile system (limit to 24F, 9 mm in diameter). In the series
eported by Webb and colleagues,13 vascular trauma ac-
ounted for 50% of the mortality and significant morbidity
n 2 patients. All patients required surgical repair and clo-
ure of the access site.18 The incidence of aortic stenosis in
atients 75 years and older is 3%,4 but the incidence of
eripheral arterial disease in the same cohort is 19.1%19
ith most of the pathology concentrated in the aortoil-
ofemoral region; therefore, the retrograde arterial approach
o the aortic valve may have limited applicability if made
vailable to a larger population. Furthermore, echocardio-
raphic evaluation of the ascending, transverse, and de-
cending thoracic aortas revealed complex plaques in
9.3% to 25% of the patients evaluated.20-22 Retrograde
avigation with a large catheter-based system in the tho-
acic aorta and in particular negotiation of the transverse
rch and ascending aorta may lead to serious embolization
efore reaching the aortic valve. The apex of the left
entricle is in contrast, in direct line with the aortic valve,
nd although care must be taken to avoid trauma to the
itral valve and chordae tendinae, the native aortic valve
s crossed in an antegrade fashion in the direction of blood
ow. This permits a shorter and stiffer delivery system that
llows easier and more precise positioning and placement of a
42 The Journal of Thoracic and Cardiovascular Surgery ● Mayhe prosthesis. Both the antegrade venous and retrograde
rterial approaches suffer from the necessary use of long,
exible catheter systems that are more difficult to precisely
ontrol as the great vessels move with respect to the heart
ith each systole.23 To combat perivalvular leaks, future
alves are planned with larger cuffs requiring 33 French
atheters making the transapical approach the only option.
Proper positioning of the prosthesis in the appropriate
ortic annular position is critical to the success of this
rocedure. Proper positioning avoids perivalvular leak, ob-
truction of the mitral valve apparatus, compromise of the
oronary ostia, and embolization of the device itself. It is
ot clear at present which imaging modality fluoroscopy or
chocardiography or a combination will best serve the needs
f closed heart procedures. In most institutions, cardiac
urgeons who interpret 2-dimensional renditions of 3-di-
ensional cardiac structures on a regular basis will find
ither of these modalities lend themselves comfortably to
heir expertise.
The case reported by Ye and colleagues9 was by fortune
lone flawlessly successful. The potential for complications
ith this new procedure is not yet well appreciated. Risks
nique to this approach likely include access site injury,
alve malposition, embolization, perivalvular leak, and car-
iac perforation. However, there will no doubt be future
eports of yet unforeseen complications in all of the ap-
roaches described, some necessitating surgical interven-
ion.13 Cardiac surgeons routinely performing considerably
ore complex procedures are best able to deal with their
omplications.
The authors9 have conspicuously avoided the use of
he word “percutaneous.” It seems that whenever that
erm is used with respect to cardiac procedures, surgeons
bdicate their responsibility to remain intimately involved
nd ensure better outcomes for their patients. The relatively
nproven outcome and inherent risks of this new therapy
rgue for mandatory surgical involvement in patient selec-
ion, an assessment of treatment alternatives or surgical
ptions should complications occur, and a fair analysis of
utcomes.
There is no doubt that cardiopulmonary bypass and open
urgery under direct vision in a still and bloodless field have
ed to major advances in surgical procedures over the past
0 years. In the prior 50 years, however, intrepid thoracic
urgeons pioneered the instruments and methods for closed
eart surgery that were willingly surrendered with the ad-
ent of cardiopulmonary bypass. The advent of catheter-
ased techniques for intracardiac procedures calls for
econsideration by cardiac surgeons of the benefits of
irect transchamber approaches not only for aortic ste-
osis but also for congenital and acquired ventricular
eptal defects, atrial septal defects, mitral valve disease,
nd ventricular reconstruction. In adapting to evolving
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Llosed heart surgery methods, cardiac surgeons must be
repared to go back to the future.
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